Must wonder if exerpt below resulted in a less impactful positive regarding the Phase 1 announcement. Sounds like it is more a matter of a process/measuring problem than actual results...so perhaps typical tweaking situation? Again, I am not a scientist or researcher, obviously. That said, would have been great if tests resulted in consistent reduction read of NF-kB as well...in addition to other reasons already given for pursuing Psoriasis treatment first, perhaps this had some influence as well?
<<One of the oral dosing regimens within the study also showed NF-kB reduction, when data was normalized via this newly developed PD assay, although observations for NF-kB activity were generally less consistent than the STAT 3 results. This was attributed to the novel PD assay not being optimized for NF-kB and that in future studies, the incubation period for the NF-kB samples should be changed to account for this finding. Analyses of the remaining regimens is ongoing.>>
